More recently other pan-ErbB inhibitors have been shown to be beneficial in reversing or preventing diabetes-induced vascular dysfunction (Akhtar et al., 2019; Akhtar et al., 2020b) and as such pan-ErbB inhibition might prove to be a useful strategy in the treatment of diabetes induced vascular complications. The gene discussed is EGFR; the disease is diabetes mellitus.